However this is a promising outlook for patients displaying a poor response to initial stages of chemotherapy.3 Another point of interest shows the capability of miR 34a to “inhibit proliferation and migration of breast cancer through downregulation of Bcl-2 and SIRT1”.30 This evidence concerns the gene BCL2 and breast carcinoma.